Please use this identifier to cite or link to this item:
Title: TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response.
Authors: López-Gómez, Carlos
Oliver-Martos, Begoña
Pinto-Medel, María-Jesús
Suardiaz, Margarita
Reyes-Garrido, Virginia
Urbaneja, Patricia
Fernández, Óscar
Leyva, Laura
metadata.dc.subject.mesh: Adult
CD4-Positive T-Lymphocytes
Gene Expression
Jurkat Cells
Middle Aged
Multiple Sclerosis
Polymerase Chain Reaction
Protein Isoforms
RNA, Messenger
Receptors, TNF-Related Apoptosis-Inducing Ligand
TNF-Related Apoptosis-Inducing Ligand
Issue Date: 3-Mar-2015
Abstract: We aimed to assess the effects of interferon β (IFNβ) treatment on the expression of the splice variants of the Tumour necrosis factor-Related Apoptosis Inducing Ligand (TRAIL) and its receptors in different cell subpopulations (CD14+, CD4+ and CD8+) from patients with multiple sclerosis (MS), and to determine whether this expression discriminated responders from non-responders to IFNβ therapy. We examined mRNA expression of the TRAIL and TRAIL receptors variants in patients with MS, at baseline and after one year of IFNβ therapy, according to responsiveness to this drug. Long-term therapy with IFNβ increased the expression of TRAIL-α in T cell subsets exclusively from responders and decreased the expression of the isoform 2 of TRAILR-2 in monocytes from responders as well as non-responders. Lower expression of TRAIL-α, and higher expression of TRAIL-β in monocytes and T cells, was found before the onset of IFNβ therapy in patients who will subsequently become responders. Baseline expression of TRAILR-1 was also significantly higher in monocytes and CD4+ T cells from responders. The present study shows that long-term IFNβ treatment has a direct influence on TRAIL-α and TRAILR-2 isoform 2 expression. Besides, receiver operating characteristic analysis revealed that the baseline expression of TRAIL-α in monocytes and T cells, and that of TRAILR-1 in monocytes and CD4+ T cells, showed a predictive value of the clinical response to IFNβ therapy, pointing to a role of TRAIL system in the mechanism of action of IFNβ in MS that will need further investigation.
metadata.dc.identifier.doi: 10.1136/jnnp-2014-309932
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC4752633.pdf754,16 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons